{
  "company": {
    "ticker": "GILD",
    "name": "Gilead Sciences Inc.",
    "category": [
      "Biotech"
    ],
    "sector": "Healthcare",
    "subCategory": "Biotech",
    "cik": "0000882095"
  },
  "reports": [
    {
      "filing": {
        "accessionNumber": "0000882095-25-000047",
        "filingDate": "2025-11-07",
        "reportDate": "2025-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/gild-20250930.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "reducing",
        "revenue": 7769,
        "netIncome": 3052,
        "operatingCashFlow": 6692,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Successfully defended Biktarvy patent challenges, extending exclusivity to 2036",
        "customerConcentration": 60,
        "geographicBreakdown": {
          "US": 68,
          "Europe": 20,
          "RestOfWorld": 12
        },
        "capexAmount": 358,
        "capexGrowth": null,
        "partnerships": [
          "LEO Pharma - STAT6 program licensing",
          "Galapagos potential company separation"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Ongoing patent litigation",
          "Product liability lawsuits"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Gilead delivered strong Q3 earnings with $7.8B revenue and $3.1B net income, driven by robust HIV and oncology portfolios. Successfully defended key patents and maintained strategic collaborations while managing operational expenses.",
        "keyQuotes": [
          "Successfully negotiated settlement agreements extending Biktarvy patent protection",
          "Continuing to invest in strategic partnerships like LEO Pharma's STAT6 program"
        ],
        "marketData": {}
      },
      "quarter": "Q3 2025",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2025,
        "fiscalQuarter": 3,
        "fiscalYear": 2025,
        "quarter": "Q3 2025",
        "reportDate": "2025-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-25-000032",
        "filingDate": "2025-08-07",
        "reportDate": "2025-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209525000032/gild-20250630.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 7054,
        "netIncome": 1960,
        "operatingCashFlow": 2584,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Received FDA approval for Yeztugo, first twice-yearly HIV PrEP option",
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 71.4,
          "Europe": 16.7,
          "RestOfWorld": 11.9
        },
        "capexAmount": 211,
        "capexGrowth": null,
        "partnerships": [
          "LEO Pharma strategic partnership for STAT6 programs",
          "Ongoing collaboration with Galapagos",
          "Arcus collaboration"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Clinical hold on HIV treatment trials GS-1720/GS-4182",
          "Ongoing patent litigation with generic manufacturers"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Gilead delivered solid Q2 2025 financial performance with strong HIV product sales and continued investment in oncology and virology R&D. The company maintains a positive outlook with strategic partnerships and new product approvals.",
        "keyQuotes": [
          "We are committed to advancing innovative medicines to prevent and treat life-threatening diseases",
          "Received FDA approval for Yeztugo, the first and only twice-yearly HIV PrEP option available in the U.S."
        ],
        "marketData": {}
      },
      "quarter": "Q2 2025",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2025,
        "fiscalQuarter": 2,
        "fiscalYear": 2025,
        "quarter": "Q2 2025",
        "reportDate": "2025-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-25-000012",
        "filingDate": "2025-05-07",
        "reportDate": "2025-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/gild-20250331.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 6667,
        "netIncome": 1315,
        "operatingCashFlow": 1757,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Biktarvy sales increased primarily due to higher demand, including patients switching from Genvoya and other Gilead HIV products",
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 69.4,
          "Europe": 16.3,
          "RestOfWorld": 13.7
        },
        "capexAmount": 104,
        "capexGrowth": null,
        "partnerships": [
          "LEO Pharma collaboration for STAT6 programs",
          "Amendment with Galapagos for potential spin-off"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "neutral",
        "summary": "Gilead delivered flat revenues of $6.7B with improving profitability, driven by strong HIV product sales and cost management. The company continues to invest in R&D and strategic partnerships while navigating market challenges.",
        "keyQuotes": [
          "We are committed to advancing innovative medicines to prevent and treat life-threatening diseases",
          "HIV product sales increased 6% primarily due to higher demand and higher average realized price"
        ],
        "marketData": {}
      },
      "quarter": "Q1 2025",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2025,
        "fiscalQuarter": 1,
        "fiscalYear": 2025,
        "quarter": "Q1 2025",
        "reportDate": "2025-03-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-25-000006",
        "filingDate": "2025-02-28",
        "reportDate": "2024-12-31",
        "form": "10-K",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/gild-20241231.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": 6,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 7569,
        "netIncome": 1783,
        "operatingCashFlow": 10828,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Expected to see continued increases in demand overall, bolstered by HIV business growth",
        "customerConcentration": 90,
        "geographicBreakdown": {
          "US": 71.4,
          "Europe": 16,
          "RestOfWorld": 12.6
        },
        "capexAmount": null,
        "capexGrowth": null,
        "partnerships": [
          "LEO Pharma A/S collaboration for inflammatory disease program",
          "Continued collaboration with Arcus Biosciences",
          "Seladelpar royalty buy-out from Janssen Pharmaceutica NV",
          "Cardinal Health",
          "Cencora",
          "McKesson"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Inflation Reduction Act expected to increase Medicare Part D payment obligations",
          "Potential climate-related regulatory requirements",
          "Evolving cybersecurity and data privacy regulations"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "neutral",
        "summary": "Gilead delivered 6% revenue growth driven by HIV, Oncology, and Liver Disease product sales. Net income declined significantly due to R&D impairment charges, particularly related to Trodelvy. The company maintains a cautious outlook for 2025 with expectations of continued product demand.",
        "keyQuotes": [
          "We look forward to the regulatory decisions for twice-yearly lenacapavir for HIV prevention",
          "We plan to continue investing in our business and R&D pipeline both internally and externally",
          "Our ability to deliver on our strategy and 2025 objectives is subject to a number of uncertainties"
        ],
        "marketData": {}
      },
      "quarter": "Q4 2024",
      "quarterInfo": {
        "calendarQuarter": 4,
        "calendarYear": 2024,
        "fiscalQuarter": 4,
        "fiscalYear": 2024,
        "quarter": "Q4 2024",
        "reportDate": "2024-12-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-24-000028",
        "filingDate": "2024-11-12",
        "reportDate": "2024-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209524000028/gild-20240930.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "lowered",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 7545,
        "netIncome": 1253,
        "operatingCashFlow": 7853,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 72.3,
          "Europe": 15.5,
          "RestOfWorld": 12.3
        },
        "capexAmount": 376,
        "capexGrowth": null,
        "partnerships": [
          "Arcellx collaboration for CART-ddBCMA",
          "Arcus ongoing collaboration"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "FDA accelerated approval withdrawal for Trodelvy",
          "Patent litigation challenges"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": false,
        "managementTone": "defensive",
        "overallSentiment": "bearish",
        "summary": "Gilead reported mixed Q3 results with cautious outlook, facing challenges in oncology portfolio and ongoing litigation. Company is reducing workforce and experiencing margin pressure while maintaining solid HIV product revenue.",
        "keyQuotes": [
          "We made a strategic decision to discontinue our clinical development program in metastatic NSCLC for Trodelvy",
          "We recorded a partial impairment charge of $1.8 billion related to NSCLC IPR&D intangible asset"
        ],
        "marketData": {}
      },
      "quarter": "Q3 2024",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2024,
        "fiscalQuarter": 3,
        "fiscalYear": 2024,
        "quarter": "Q3 2024",
        "reportDate": "2024-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-24-000022",
        "filingDate": "2024-08-08",
        "reportDate": "2024-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209524000022/gild-20240630.htm"
      },
      "insights": {
        "guidanceTone": "confident",
        "guidanceDirection": "maintained",
        "bookingsGrowth": 5,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 6954,
        "netIncome": 1614,
        "operatingCashFlow": 3544,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 71,
          "Europe": 16,
          "RestOfWorld": 13
        },
        "capexAmount": 235,
        "capexGrowth": null,
        "partnerships": [
          "Merus N.V. research collaboration",
          "Xilio Therapeutics license agreement",
          "CymaBay Therapeutics acquisition"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Gilead delivered solid Q2 2024 performance with 5% revenue growth driven by strong HIV, Oncology, and Liver Disease product sales. The company completed the CymaBay acquisition, adding seladelpar to its portfolio, and is actively managing expenses through workforce reductions.",
        "keyQuotes": [
          "We are committed to advancing innovative medicines to prevent and treat life-threatening diseases",
          "We are a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades"
        ],
        "marketData": {}
      },
      "quarter": "Q2 2024",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2024,
        "fiscalQuarter": 2,
        "fiscalYear": 2024,
        "quarter": "Q2 2024",
        "reportDate": "2024-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-24-000013",
        "filingDate": "2024-05-08",
        "reportDate": "2024-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209524000013/gild-20240331.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "not_provided",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 6686,
        "netIncome": -4170,
        "operatingCashFlow": 2219,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 69.3,
          "Europe": 17.3,
          "RestOfWorld": 13.4
        },
        "capexAmount": 105,
        "capexGrowth": null,
        "partnerships": [
          "Merus N.V. research collaboration",
          "Xilio Therapeutics license agreement"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Patent litigation with generic manufacturers",
          "Pre-exposure prophylaxis patent disputes"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "defensive",
        "overallSentiment": "bearish",
        "summary": "Gilead reported a challenging Q1 2024 with significant losses driven by acquired in-process R&D charges and an impairment related to the CymaBay acquisition. While product sales grew 5%, net loss was $4.2 billion, primarily due to substantial non-cash expenses.",
        "keyQuotes": [
          "We are committed to advancing innovative medicines to prevent and treat life-threatening diseases",
          "The decrease was primarily driven by an acquired in-process research and development charge of $3.9 billion related to the acquisition of CymaBay"
        ],
        "marketData": {}
      },
      "quarter": "Q1 2024",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2024,
        "fiscalQuarter": 1,
        "fiscalYear": 2024,
        "quarter": "Q1 2024",
        "reportDate": "2024-03-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-24-000007",
        "filingDate": "2024-02-23",
        "reportDate": "2023-12-31",
        "form": "10-K",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209524000007/gild-20231231.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 7149,
        "netIncome": 1436,
        "operatingCashFlow": 8006,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 71.6,
          "Europe": 15.9,
          "OtherInternational": 12.5
        },
        "capexAmount": null,
        "capexGrowth": null,
        "partnerships": [
          "Assembly Biosciences",
          "Tentarix Biotherapeutics",
          "Arcellx",
          "Arcus Biosciences",
          "Compugen",
          "Nurix Therapeutics"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Drug pricing legislation",
          "Medicare price negotiations",
          "State-level drug pricing reviews"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Gilead delivered solid financial performance in 2023, with total revenues of $27.1 billion and net income of $5.7 billion. HIV and oncology product sales showed strong growth, while COVID-19 treatment Veklury sales declined due to lower hospitalization rates.",
        "keyQuotes": [
          "We continued to invest in our business and research and development pipeline through acquisitions and collaborations.",
          "During 2023, we continued to advance our portfolio and broaden available therapies while delivering continued growth in our HIV and Oncology product sales."
        ],
        "marketData": {}
      },
      "quarter": "Q4 2023",
      "quarterInfo": {
        "calendarQuarter": 4,
        "calendarYear": 2023,
        "fiscalQuarter": 4,
        "fiscalYear": 2023,
        "quarter": "Q4 2023",
        "reportDate": "2023-12-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-23-000031",
        "filingDate": "2023-11-07",
        "reportDate": "2023-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209523000031/gild-20230930.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 7051,
        "netIncome": 2180,
        "operatingCashFlow": 5837,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": 25,
        "geographicBreakdown": {
          "US": 71.1,
          "Europe": 14.8,
          "OtherInternational": 14.1
        },
        "capexAmount": 370,
        "capexGrowth": null,
        "partnerships": [
          "Arcellx collaboration for CART-ddBCMA",
          "Acquired XinThera",
          "Acquired Tmunity"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Patent litigation with generic manufacturers",
          "Product liability lawsuits"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Gilead delivered strong Q3 2023 financial performance with robust revenue of $7.051 billion and net income of $2.180 billion. The company continues to focus on strategic acquisitions and collaborations in the cell therapy and oncology space while defending its intellectual property.",
        "keyQuotes": [
          "We believe these cases are without merit",
          "We intend to vigorously defend ourselves in these actions"
        ],
        "marketData": {}
      },
      "quarter": "Q3 2023",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2023,
        "fiscalQuarter": 3,
        "fiscalYear": 2023,
        "quarter": "Q3 2023",
        "reportDate": "2023-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-23-000025",
        "filingDate": "2023-08-04",
        "reportDate": "2023-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209523000025/gild-20230630.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 6564,
        "netIncome": 1039,
        "operatingCashFlow": 4082,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 72.7,
          "Europe": 15.1,
          "OtherInternational": 12.2
        },
        "capexAmount": 248,
        "capexGrowth": null,
        "partnerships": [
          "Arcellx collaboration for CART-ddBCMA",
          "XinThera acquisition",
          "Tmunity acquisition"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Patent challenges for HIV drugs",
          "Antitrust litigation related to HIV medications"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "neutral",
        "summary": "Gilead delivered steady Q2 2023 financial performance with robust product sales in HIV and oncology. The company continues to invest in strategic acquisitions and collaborations while defending its intellectual property through ongoing litigation.",
        "keyQuotes": [
          "We continue to see strong performance across our key therapeutic areas",
          "Strategic collaborations and acquisitions remain a key part of our growth strategy"
        ],
        "marketData": {}
      },
      "quarter": "Q2 2023",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2023,
        "fiscalQuarter": 2,
        "fiscalYear": 2023,
        "quarter": "Q2 2023",
        "reportDate": "2023-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-23-000017",
        "filingDate": "2023-05-03",
        "reportDate": "2023-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209523000017/gild-20230331.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "expanding",
        "revenue": 6352,
        "netIncome": 1010,
        "operatingCashFlow": 1744,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Higher product sales in HIV, Cell Therapy and Trodelvy",
        "customerConcentration": 64,
        "geographicBreakdown": {
          "US": 70.1,
          "Europe": 17,
          "OtherInternational": 12.9
        },
        "capexAmount": 109,
        "capexGrowth": null,
        "partnerships": [
          "Acquired Tmunity Therapeutics",
          "Strategic collaboration with Arcellx",
          "Licensed investigational molecule from Nurix"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Multiple patent litigation cases",
          "FDA regulatory reviews"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Gilead delivered strong Q1 2023 performance with 13% HIV product sales growth and significant oncology/cell therapy expansion. The company continues to invest in strategic acquisitions and maintain a robust pipeline across multiple therapeutic areas.",
        "keyQuotes": [
          "We are committed to advancing innovative medicines to prevent and treat life-threatening diseases",
          "Completed acquisition of Tmunity, which provides preclinical and clinical programs"
        ],
        "marketData": {}
      },
      "quarter": "Q1 2023",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2023,
        "fiscalQuarter": 1,
        "fiscalYear": 2023,
        "quarter": "Q1 2023",
        "reportDate": "2023-03-31"
      },
      "analyzedSuccessfully": true
    }
  ],
  "totalFetched": 12,
  "successfulAnalyses": 11,
  "lastUpdated": "2026-01-21T19:43:51.618Z"
}